{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Abraxane&page=27", "query": { "intervention": "IV Abraxane", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 1429, "total_pages": 143, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Abraxane&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Abraxane&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T19:40:40.698Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00054028", "title": "Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Breast Cancer", "Stage IIIB Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "suramin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 31, "start_date": "2002-12", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054028" }, { "nct_id": "NCT01057264", "title": "HAI Abraxane With Gemcitabine and Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "HAI Abraxane", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2010-01", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01057264" }, { "nct_id": "NCT05704985", "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Solid Tumor", "Colorectal Cancer", "Pancreas Cancer", "Non Small Cell Lung Cancer", "Head and Neck Cancer", "Gynecologic Cancer", "Skin Cancer", "Kidney Cancer" ], "interventions": [ { "name": "DK210 (EGFR)", "type": "BIOLOGICAL" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Immune checkpoint blockers", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "DEKA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2023-04-03", "completion_date": "2025-10", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 7, "location_summary": "Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Manhasset", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05704985" }, { "nct_id": "NCT03393884", "title": "Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "IMNN-001", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Imunon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 130, "start_date": "2018-09-05", "completion_date": "2026-05-30", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Newport Beach, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Newport Beach", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03393884" }, { "nct_id": "NCT00004093", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Navelbine", "type": "DRUG" }, { "name": "Taxol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "1999-08", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004093" }, { "nct_id": "NCT00733408", "title": "Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "HER2-negative Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "erlotinib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 59, "start_date": "2008-04-23", "completion_date": "2017-09-28", "has_results": true, "last_update_posted_date": "2018-12-04", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 17, "location_summary": "Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Lewiston", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00733408" }, { "nct_id": "NCT00002684", "title": "Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Urethral Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1995-05", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2013-07-03", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002684" }, { "nct_id": "NCT00575952", "title": "Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mixed Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Squamous Cell Carcinoma", "Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIC Uterine Corpus Cancer", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 27, "start_date": "2008-01-17", "completion_date": "2016-07-16", "has_results": false, "last_update_posted_date": "2017-08-24", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 9, "location_summary": "Hartford, Connecticut • New Britain, Connecticut • Chicago, Illinois + 6 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00575952" }, { "nct_id": "NCT00005026", "title": "Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": null, "start_date": "2000-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005026" }, { "nct_id": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Cervical Neoplasms", "Endometrial Neoplasms", "Squamous Cell Carcinoma of Head and Neck", "Gallbladder Neoplasms", "Cholangiocarcinoma", "Esophageal Neoplasms", "Triple Negative Breast Neoplasms", "Hepatocellular Carcinoma", "Urinary Bladder Neoplasms", "Ovarian Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "Pembrolizumab/Vibostolimab Co-Formulation", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 611, "start_date": "2021-09-16", "completion_date": "2025-08-05", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-15T19:40:40.698Z", "location_count": 14, "location_summary": "Anchorage, Alaska • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05007106" } ] }